Dolotram Plus 37,5 mg AND 325 mg FC tablets.
PDF Leaflet Revision Date: 22 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Management of moderate to moderately severe pain in adults.
Dosage (summary)
1-2 tablets every 4-6 hours as needed, max 8 tablets/day.
Onset of Action / Duration
Onset: 2-3 hours, Duration: 6-8 hours
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; safety in lactation not established.
Key Drug Interactions
- MAO inhibitors
- Alcohol
- Warfarin
- CNS depressants
Contraindications
- Hypersensitivity to tramadol or paracetamol
- Moderate to severe hepatic impairment
- Respiratory depression
- Epilepsy not controlled by treatment
Common side effects
- Dizziness
- Nausea
- Constipation
- Somnolence
- Headache
Counselling Points
- Do not exceed recommended dose
- Avoid alcohol
- Monitor for signs of overdose
- Inform about potential drowsiness
Serious warnings
- Risk of overdose leading to severe liver damage
- Potential for dependence and abuse
- Risk of seizures
Important Disclaimer
The Dolotram Plus 37,5 mg AND 325 mg FC tablets. professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
